Melanotan I vs BPC-157
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | BPC-157 |
|---|---|---|
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. |
| Best For |